J.P. Morgan Healthcare Confab Live Blog: Day Three

 

SAN FRANCISCO (TheStreet) -- Here we are, the final live blog of the J.P. Morgan Healthcare Conference 2014. It's Wednesday, hump day, featuring presentations from MannKind (MNKD), Keryx Pharma  (KERX), Alexion Pharma (ALXN), Geron (GERN) and Sarepta Therapeutics (SRPT).

By now, you know the drill. I will be posting news updates and analysis throughout the day, live from the presentation rooms and breakout (Q&A) sessions. You can also follow me on Twitter, my handle is @adamfeuerstein. Your best bet is to check back into the live blog several times throughout the day. Feel free to ping me with questions and comments. I'll do my best to respond and keep the live blog as interactive as possible.

Here's my schedule for the day, preliminary, subject to change. All times Eastern.

MannKind 10:30 am
Keryx 11:30 am
Alexion 12:30 pm
Newlink Genetics (NLNK) 1 pm
Bluebird Bio  (BLUE) 1:30 pm
Geron 4:30 pm
Exelixis (EXEL) 5 pm
Morphosys 7 pm
Sarepta Therapeutics 7:30 pm

Sleep: 8 pm until well into tomorrow.


-- Reported by Adam Feuerstein in San Francisco.  

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Musk's Tweets About Unions Draw Fire From United Auto Workers

Musk's Tweets About Unions Draw Fire From United Auto Workers

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Gap Drops After Hours on Disappointing Earnings, Weak Same-Store Sales

Gap Drops After Hours on Disappointing Earnings, Weak Same-Store Sales

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz